Approval · Notice of Compliance 12146 · 2011
APO-NARATRIPTAN: Notice of Compliance 12146
Issued March 11, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12146
- Date
- March 11, 2011
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Migraine therapy
- Canadian reference product
- AMERGE (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-NARATRIPTAN | 02365499 | Approved |
| APO-NARATRIPTAN | 02365502 | Approved |
Medicinal ingredients
- NARATRIPTAN HCL 1 MG per TAB
- NARATRIPTAN HCL 2.5 MG per TAB